For pharmacies, clinics, insurers and employers

Patients keep the weight off. You keep the patient.

Less is More finds each patient's lowest effective maintenance dose and adjusts it month by month, so the weight stays off and treatment keeps working. A course of injections becomes years of care. Clinician-led, white-label and built to run inside the service you already operate.

Everyone has built the front door to GLP-1s. Nobody has built what comes after it, which is where the durable margin is likely to sit.

Same customer, five years
£ start month 6 year 5 the course ends here maintenance still yours in year five Revenue from one customer. Illustrative.
selling the course selling maintenance
Why now

Your best customers are leaving inside a year

They lose the weight, they stop, the weight comes back and most of them start again — with somebody. The only question is whether it is with you.

1.6m
UK adults used a GLP-1 or GIP medicine for weight loss last year
UCL / BMC Medicine, 2026
64.8%
of weight-loss patients stopped within a year. That is your churn rate.
JAMA Network Open, 2025
36.3%
of them started again in the same year. Someone got that revenue.
JAMA Network Open, 2025
0.5–1.5m
people in the UK are stopping, stepping down or frightened of regain right now
Commercial estimate, not a counted population
The arithmetic

A smaller monthly number, for a great deal longer

We look for the lowest dose that still works, so the drug line comes down. That is deliberate. A smaller prescription running for years adds up to more than a large one that stops at month six, and the service fee alongside it is margin that does not move with the price of the medicine.

Selling the course

High monthly value, six months, then they are gone. As the medicine gets cheaper, that business competes mainly on price.

Selling maintenance

Lower monthly value, but years of it, plus a service fee that has nothing to do with the price of the drug.

The churn you already have

Two thirds of your weight-loss patients leave within a year and a third of them start again somewhere. Keeping even some of them changes the numbers.

What you own at the end

A customer with years of history on your platform, and a reason to stay that has nothing to do with what you charge per pen.

What you get

One integration. Four things you do not have to build.

A per-patient fee, under your brand. API-first, so it fits into what you already run rather than replacing it.

A reason for patients to stay

Dose optimisation, safety reviews, side-effect management and structured tapering. The ongoing work that keeps the result, and keeps the customer.

Your brand throughout

White-label throughout. We sit behind your service and you keep the relationship. Nobody needs to know our name.

Numbers you can show your board

Retention, dosing, weight and outcomes, captured consistently enough to report on rather than merely display.

The behaviour change that makes it stick

Support across sleep, nutrition and movement, plus integration with the adherence tools your members already use.

How it works

How we hold on to them

Everyone else pushes the dose up. We do the opposite, under clinical supervision, because a dose someone can live with is a dose they stay on.

1

Start low

Below the drama of a full dose, inside boundaries your clinician sets for that person.

2

Listen

Appetite and side effects on a consistent scale, plus weight, adherence and the wearables they already own.

3

Adjust

We propose a change against a written protocol. Your clinician approves, amends or rejects it. Nothing moves without them.

4

Hold it

Keep the result at the lowest workable dose while the habits do the work the medicine cannot.

Clinical governance

We understand you are taking on clinical risk

So we built this to be inspected. Your medical director, your information governance lead or a regulator can see exactly how any decision was reached — and see that it could not have been reached any other way.

✓

Your clinician decides, every time

We propose. We never prescribe, dispense or change a treatment. Every proposal is marked as requiring their approval.

✓

You set the limits, we cannot cross them

A floor, a ceiling, a maximum step and a minimum interval, per patient. Enforced separately from the rules, so even a bad rule cannot get past them.

✓

No AI picks a dose

Doses come from a written, versioned, testable protocol your clinician signs off. Language models handle language, not arithmetic.

✓

Ask us in a year and we can still show you

Same inputs, same protocol version, same answer — provably. Every proposal, approval and rejection is named and timestamped.

✓

Safety comes first, literally

Red flags are checked before anything else. They hold the dose, send the patient to urgent care and reach one of your people straight away.

✓

You can prove what changed and when

Every patient is tagged with the protocol version they are on, so you can answer which approach produced which outcome.

Inside the platform

Your clinicians see the eleven who need them today

Not the four hundred who do not. Everyone else sits safely inside their limits, and the ones who need attention arrive with the reasoning already written.

Each row says which rule fired and why, in a sentence your clinician can agree or disagree with. Nothing here has changed anyone's treatment.

See the platform

Today's queue · illustrative
Patient LM-1081
Red flag reported. Dose held, clinician alerted, patient routed to urgent care.
Immediate
Patient LM-1054
Appetite high on 6 of 7 days, no side effects, adherence 87%. Proposing one step up.
Step up
Patient LM-1044
Above threshold on only 3 of 7 days; 5 are needed before acting. No change proposed.
No change
Patient LM-1045
At the ceiling for 43 weeks with no response. Proposing a molecule review, not a further increase.
Review
What your members see

Thirty seconds a day, and a reason for everything

Adherence is where these programmes usually fall over. We ask for very little and explain every change in plain English.

A check-in they will actually do

Five questions on appetite, plus side effects and whether they took the dose. Short enough to finish on the way to work.

The trend, not today's number

Weight is asked for weekly and shown as a smoothed line. For someone frightened of putting it back on, a daily number does more harm than good.

No mystery dose changes

They are told why, in the same words their clinician saw. A dose going down is framed as the plan working.

A straight answer in an emergency

Anything urgent goes to urgent care, not into a chat queue. The app never pretends it can manage a crisis.

Shown here so you can see how the service is designed. This page is for partners. Patients can find our own service at lessismore.living.

Who we work with

Who we work with

Organisations whose GLP-1 business is a transaction today and could be a long-term relationship instead.

Private medical insurers

You carry the cost and the risk

The lowest workable dose costs you less every month, and members who keep the weight off do not come back as claims.

Employers and brokers

You design the scheme

Offer a GLP-1 benefit you can defend to finance, without unbounded cost or an awkward conversation when people come off it.

Pharmacies and prescribers

You dispense at scale

As the medicine gets cheaper, dispensing alone starts to look like a price war. Maintenance is the part nobody can undercut, and it keeps the customer on your list.

Digital weight-loss clinics

You own the front door

You spend to acquire someone and lose them at month six. Maintenance is how that acquisition cost pays back three times over.

Wellness platforms

You change behaviour

Add the clinical layer you do not have, and turn coaching into medically supervised maintenance you can measure.

Fitness, nutrition and diagnostics

You already measure

Attach muscle preservation, better food and biomarker tracking to a population that is already engaged.

Who you would be working with

We build ventures in regulated markets

Less is More is built by System Two, which has spent nearly twenty years creating and testing ventures in awkward, regulated, behaviour-heavy markets.

Eight exits and counting

Including ventures sold to British Gas, GSK and Octopus.

We have done healthcare before

Regulated senior care, oral health, sleep apnoea devices and food reformulation.

Billions raised

In debt and equity across founder-led businesses in energy, health and technology.

We test adherence, we do not assume it

Most care-pathway ventures die because somebody assumed people would stick with it. We started from the other end.

Book a walkthrough

Arrange a walkthrough

Half an hour, covering whichever parts matter to you: the clinician queue, the protocol in force, the guardrails, the audit trail. Tell us where to start.

We will use what you send only to reply to you.